To the Editor.—We read with great interest the article by Dr. Gissenbergh et al.1 about the reversal of rocuronium-induced neuromuscular block by Org 25969. The described reversal mechanism is highly promising both for the clinical application and in research endeavors.

This being the first description of the pharmacokinetics of Org 25969, we hoped to reconstruct the time course of the plasma concentrations of Org 25969 using the provided data. Unfortunately, the combination of the pharmacokinetic parameters (tables 6 and 7) does not permit such a reconstruction, in part due to a nonstandard method of analysis. The authors do not mention whether an exponential equation or a compartmental model was fitted to the concentrations of Org 25969 in plasma. Was either approach even attempted? The terminal elimination half-life of sugammadex could be appropriate for either a biexponential or a triexponential equation. The reported values for the areas under the plasma concentration curves are, in concept, dose dependent, and the reported values apparently reflect this. Presumably, the authors used areas under the plasma concentration curves to justify the claim of “dose-linear pharmacokinetics,” but this was not explicitly stated in the text. The reported “volume of distribution during the terminal phase” (VZ) is not routinely reported, and a comparison with the standard volumes, i.e., the initial volume of distribution for a multicompartmental model (V1), the volume of the central compartment in compartmental interpretation (V1), or the volume of distribution at steady state (VSS), is difficult if not impossible. Furthermore, because VZ was evaluated from VZ = CL/β, VZ is a function of t½β and, hence, provides no additional information. Of the routinely reported parameters, the authors provide only the estimates for the systemic clearance (CL) and the mean residence time. These two parameters do not suffice to reconstruct the time course of the plasma concentrations.

It would have been informative had the authors compared the doses of Org 25969 with the dose of rocuronium using molar units. The dose of rocuronium, 0.6 mg/kg, corresponds to approximately 1 · 10⁻⁶ mol · kg⁻¹. Given the molecular weight of Org 25969 of 2,000 Da,² the doses of Org 25969, 0.1 to 8.0 mg/kg, correspond to (0.05 to 4) · 10⁻⁶ mol · kg⁻¹. If one molecule of Org 25969 binds to one molecule of rocuronium and assuming that the whole dose of rocuronium is still present in the body 3 min after injection, then Org 25969 doses of less than 1 · 10⁻⁶ mol · kg⁻¹, corresponding to less than 2 mg/kg, would, on theoretical basis, have little chance to reverse the neuromuscular block completely. As documented by the authors, only the molar doses ofOrg 25969 higher than the molar dose of rocuronium produced the desired reversal. Therefore, Org 25969 doses of 4.0 and 8.0 mg/kg efficiently reversed the block (table 9); on the molar basis, the two doses are two and four times higher than the dose of rocuronium. The Org 25969 dose of 2 mg/kg is equimolar to that of rocuronium and produced only a marginal reversal of neuromuscular block. Consideration of the doses in molar terms strengthens the authors’ conclusion and explains why lower doses of Org 25969 could not have produced the reversal (table 9).

Vladimir Nigrovic, M.D.*, Shashi B. Bhatt, M.D., Anton Amann, Ph.D. †Medical University of Ohio, Toledo, Ohio. vnigrovic@meduohio.edu

References

In Reply:—We appreciate the interest of Nigrovic et al. in our work. The pharmacokinetic parameters that are presented in our article¹ are the results of a noncompartmental pharmacokinetic analysis. The authors of the letter are looking for parameters of a pharmacokinetic modeling analysis and wonder whether such an approach was attempted. The answer is yes. In addition to the descriptive manner in which the pharmacokinetic data of this trial were presented in the article, the plasma concentration-time data of sugammadex (Org 25969) and rocuronium were also analyzed elaborately as part of a mechanism-based pharmacokinetic-pharmacodynamic modeling analysis. The model developed in the latter analysis describes not only the time course of plasma concentrations of sugammadex, rocuronium, and the complex formed between sugammadex and rocuronium, but also the resulting time course of neuromuscular block. The results of the development and validation of that model will be the subject of a separate publication.

With regard to the second point that was raised, we agree that it may have been informative from a scientific point of view to discuss the doses in molar units, but because in practice sugammadex is dosed in units of mg/kg, we believe that it is more appropriate to use that unit in publications.

Natalie Houwing, M.Sc., François Gissenbergh, M.D., Steven Ramael, M.D., Thijs van Iersel, M.D. †Pharmerit BV, Rotterdam, The Netherlands. nhouwing@pharmerit.com

Reference

© 2006 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.
To the Editor.—We read with interest two case reports of fatal thrombotic complications after cardiopulmonary bypass.1,2 However, there are several unclear issues that the readers should become aware of. First, it is not clear whether adequate heparin levels were maintained during cardiopulmonary bypass (CPB) because activated clotting time (greater than 400–600 s*) does not necessarily reflect the efficacy of heparin anticoagulation.3

Heparin insensitivity due to antithrombin deficiency may be masked by thrombocytopения, hypofibrinogenemia, or other coagulation factor defects. At our institution, we administer hourly bolus doses of 100 U/kg heparin during CPB to prevent the decrease of plasma heparin levels. Furthermore, we frequently replete antithrombin during prolonged CPB (approximately 3 h) in suspected antithrombin-deficient cases by adding fresh frozen plasma or antithrombin concentrate (Thrombate III®; Talecris Biotherapeutics, Research Triangle Park, NC). We have previously shown that reduced antithrombin levels greatly enhance the rate and peak level of thrombin generation.4 In patients with endocarditis, prolonged CPB, or both, plasma antithrombin levels may become critically low.2 Intravascular fluidity, however, may be maintained by the balance between low procoagulant (fibrinogen, platelet) and low anticoagulant levels (antithrombin, protein C, and S; trombomodulin). Under such conditions consistent with disseminated intravascular coagulopathy, one may observe bleeding tendency. In both cases that the authors described, the administration of hemostatic blood products, platelet concentrate,1 and cryoprecipitate2 after heparin reversal seemed to have triggered thrombotic complications. Rapid extensions of thrombi suggest that uncontrolled “thrombin generation” occurred, and it is questionable whether thrombi could have been quickly dissolved by endogenous fibrinolytic system even in the absence of aprotinin or other antifibrinolytic agents.5 In the case of afibrinogenemia referenced by the authors, it is possible that normal anticoagulant function and short CPB time (36 min) limited thrombus formation locally (i.e., graft occlusion) without systemic thrombus extension.7

To further stress the importance of adequate anticoagulation, the incidence of deep venous thromboses does not seem to be increased with intraoperative use of aprotinin in the orthopedic surgery when prophylaxis for deep venous thromboses (e.g., low-molecular-weight heparin) is implemented.6 These two catastrophic cases highlight the importance of balancing procoagulant and anticoagulant components of coagulation to achieve localized hemostasis while avoiding thrombotic complications. Further clinical trials must be conducted to improve our current anticoagulant strategy.9

Kenichi A. Tanaka, M.D.,† Roman Sniecinski, M.D., ‡Emory University School of Medicine, Atlanta, Georgia. kenichi.tanaka@emoryhealthcare.org

References

(accepted for publication April 25, 2006.)

In Reply—We thank Drs. Tanaka and Sniecinski for their comments on our two reports of systemic thrombosis after cardiopulmonary bypass associated with aprotinin.1,2 They point out the possible role of antithrombin deficiency in these scenarios: This is applicable, given the settings of endocarditis, disseminated intravascular coagulation, and prolonged cardiopulmonary bypass.1,2 In the presence of antithrombin deficiency, overall thrombin production is increased.3 This thrombin excess could be a factor in the rapid development of systemic thrombosis described.1,2 How do we integrate these observations into clinical practice? Clearly, we still lack adequate data to proceed. Bolus heparin therapy in the setting of aprotinin monitored with appropriate activated clotting time is an established standard for cardiopulmonary bypass, including deep hypothermic circulatory arrest, as the authors point out in their footnote. Furthermore, we have a large experience with this technique, including in deep hypothermic circulatory arrest.4–6 To my knowledge, there is no case report of this phenomenon with bolus heparin therapy titrated to heparin level. Of course, on the basis of case reports, no comparisons can be inferred between these two standards of care with respect to this kind of event.

Systemic thrombosis after cardiopulmonary bypass is very uncommon in the presence of standardized heparin therapy. It has also been reported in the pediatric population and in the presence of aminocaproic acid.7,8 A common feature in these reports is that the onset of thrombosis is shortly after heparin reversal with protamine, often in the setting of blood component transfusion to correct ongoing bleeding. The exact etiology of this rare, but catastrophic event is probably

Anesthesiology 2006; 105:428–9

© 2006 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

In Reply—We thank Drs. Tanaka and Sniecinski for their comments on our two reports of systemic thrombosis after cardiopulmonary bypass associated with aprotinin.1,2 They point out the possible role of antithrombin deficiency in these scenarios: This is applicable, given the settings of endocarditis, disseminated intravascular coagulation, and prolonged cardiopulmonary bypass.1,2 In the presence of antithrombin deficiency, overall thrombin production is increased.3 This thrombin excess could be a factor in the rapid development of systemic thrombosis described.1,2 How do we integrate these observations into clinical practice? Clearly, we still lack adequate data to proceed. Bolus heparin therapy in the setting of aprotinin monitored with appropriate activated clotting time is an established standard for cardiopulmonary bypass, including deep hypothermic circulatory arrest, as the authors point out in their footnote. Furthermore, we have a large experience with this technique, including in deep hypothermic circulatory arrest.4–6 To my knowledge, there is no case report of this phenomenon with bolus heparin therapy titrated to heparin level. Of course, on the basis of case reports, no comparisons can be inferred between these two standards of care with respect to this kind of event.

Systemic thrombosis after cardiopulmonary bypass is very uncommon in the presence of standardized heparin therapy. It has also been reported in the pediatric population and in the presence of aminocaproic acid.7,8 A common feature in these reports is that the onset of thrombosis is shortly after heparin reversal with protamine, often in the setting of blood component transfusion to correct ongoing bleeding. The exact etiology of this rare, but catastrophic event is probably
multifactorial, including genetic factors such as factor V Leiden. Antithrombin deficiency may be another factor in this multifactorial etiology. The role of aprotinin is still to be elucidated, because there is recent evidence of an association with thrombotic risk after cardiopulmonary bypass. This area of endeavor is limited not only by a rare incidence and complex etiology, but also by a lack of real-time objective coagulation monitoring data. This information would allow analysis of the coagulation/anticoagulation imbalance to localize the lesion and direct further inquiry.

The role of antithrombin deficiency should also be interpreted in light of the thrombin inhibitor. Until recently, heparin, an indirect thrombin inhibitor, was the main anticoagulant for cardiopulmonary bypass. This will certainly shift in the future, given the arrival of bivalirudin, a direct thrombin inhibitor, as a clinical alternative to heparin for cardiac surgery with and without cardiopulmonary bypass. Moreover, the time for BIS processing was not taken into account; hence, the moment the word was played. The authors showed that implicit learning was studied during general anesthesia. So implicit learning presented as occurring at a BIS below 60 during 18.5% of the time, which is far from what learning occurs with a BIS below 60. Indeed, during word presentation, the word should have actually been associated with the word played 15–30 s earlier. This could have changed the assumption that implicit learning persists for words played during light (BIS 61–80) and adequate anesthesia as stated in the article.

Drs. Tanaka and Sniecinski have correctly highlighted antithrombin deficiency as a possible component in the etiology of systemic thrombosis after cardiopulmonary bypass. The continuing incidence of these rare, but catastrophic cases highlights the clinical necessity for better data, perhaps in the form of an international registry. This would provide a platform for further clinical trials to refine our coagulation management of cardiopulmonary bypass and improve perioperative outcomes for our patients.

John G. T. Augoustides, M.D., F.A.S.E., Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. yiandoc@hotmail.com

References


To the Editor:—We read with interest the article by Iselin-Chaves et al.1 in which implicit learning was studied during general anesthesia. Forty words were played 25 times during anesthesia, and each played word was associated with a Bispectral Index (BIS) value recorded at the moment the word was played. The authors showed that implicit learning persists for words played during light (BIS 61–80) and adequate anesthesia (BIS 41–60) but not during deep anesthesia (BIS 21–40). Because the words were repeated 25 times throughout anesthesia, each word was associated with 25 BIS values for each patient, and it is not clear whether the authors, to classify each word in a BIS category (21–40, 41–60, or 61–80), used the mean of the 25 BIS values or used the BIS range of these 25 values to be associated with each word. If the mean BIS value was used, it is possible that some of the word presentations have been played at a higher BIS value than stated in the study. So implicit learning presented as occurring at a BIS below 60 may actually have occurred at a higher BIS.

Moreover, the time for BIS processing was not taken into account; this processing is responsible for a 15- to 30-s delay between raw electroencephalogram recordings and BIS value display (depending on the “BIS Smoothing Rate” setup).2 So each BIS value associated with a word should have actually been associated with the word played 15–30 s earlier. This could have changed the assumption that implicit learning occurs with a BIS below 60. Indeed, during word presentation, BIS was above 60 during 18.5% of the time, which is far from what can be considered as an adequate anesthesia as stated in the article.

Pierre-Yves Lequeux, M.D.,* Gilbert Bejiani, M.D., Hicham Sekkat, M.D. Centre Hospitalier Universitaire-Tivoli, La Louviere, Belgium. pilequeu@ulb.ac.be

References


Implicit Memory during Isoflurane Anesthesia

Accepted for publication April 25, 2006.

Anesthesiology 2006; 105:429
Succinylcholine-induced Hyperkalemia

To the Editor.—Drs. Martyn and Richtsfeld1 have provided a great deal of useful information in their recent review article titled “Succinylcholine-induced Hyperkalemia in Acquired Pathologic States.” However, clarification is warranted regarding their statement concerning my 2003 case report of a patient who developed succinylcholine-induced hyperkalemia.2 Martyn and Richtsfeld state, “Another report of hyperkalemia with succinylcholine implicating pancreatitis as the etiologic factor actually had an upper motor neuron lesion of several weeks duration.” Actually, in my article, little attempt was made to implicate pancreatitis as the causal pathologic state. As was stated in my report, the patient’s upper motor neuron lesion was a traumatic cervical spine injury that occurred 14 months, rather than several weeks, before the hyperkalemic response to succinylcholine. The discussion that followed was meant to challenge the traditional views of how long extrajunctional neuromuscular receptors persist after traumatic upper motor neuron injury. In their review, Martyn and Richtsfeld have provided important information regarding the duration of these changes in acquired states. Importantly, they have made clear succinylcholine’s potential morbidity when used in critically ill patients who experience muscle atrophy, whether due to pharmacologic denervation or bed rest from critical illness (our patient had been critically ill for approximately 30 days and, in retrospect, resulting muscle atrophy was the most likely etiology of the patient’s hyperkalemic response). The question that cannot be answered definitively by the review article of Martyn and Richtsfeld is, at what point does the risk/benefit ratio of a medication become unacceptable? As the potential morbidity of a therapy increases, the indications for that therapy become narrower. However, it remains difficult to determine when the risk of a therapy becomes absolutely prohibitive. My case report presented the conundrum of an obese, hypoxic, uncooperative patient who required tracheal intubation and who, by examination, had a potentially difficult airway. This type of patient encounter occurs sporadically and unpredictably and cannot be studied prospectively in any meaningful way. In 22 yr of clinical practice, I have personally witnessed several near-airway catastrophes that followed the alternative use of long-acting nondepolarizing muscle relaxants in similar situations. Therefore, I continue to express the opinion offered in the last paragraph of my case report: “Recognizing that the hyperkalemic response to succinylcholine is unpredictable and that there are currently no criteria to establish those definitively at risk, it is uncertain that alternative administration of a long-acting nondepolarizing muscle relaxant would result in less overall morbidity when administered to a series of patients under similar circumstances.” Unfortunately, clinicians will continue to face these difficult therapeutic decisions, albeit with more wisdom instilled by the work of Martyn and Richtsfeld and others.

J. Mark Matthews, M.D., University of Missouri and St. Luke’s Hospital, Kansas City, Missouri. jmarkmatthews1@earthlink.net

References


(Received for publication May 1, 2006.)
In Reply:—Dr. Matthews takes exception to a statement in the review\(^1\) that refers to his publication.\(^2\) The statement reads as follows: “Another report of hyperkalemia with succinylcholine implicating pancreatitis as the etiologic factor actually had an upper motor neuron lesion of several weeks’ duration.” Dr. Matthews claims that little attempt was made to implicate pancreatitis as the causal pathologic state in their case report.

His report\(^2\) is titled “Succinylcholine-induced Hyperkalemia and Rhabdomyolysis in a Patient with Necrotizing Pancreatitis.” The end of the first paragraph of that report makes the following statement: “We report a case of succinylcholine-induced hyperkalemic cardiac arrest and subsequent myoglobinemic renal failure occurring in a patient with severe necrotizing pancreatitis.” Based on these statements, I concluded that pancreatitis was being implicated as the etiologic factor for the hyperkalemic response.

The risk-benefit ratio of the utility of a drug cannot be generalized and applied to all clinical situations. The decision to proceed or not with the administration of the drug (succinylcholine) has to be individualized based on the available information at that time for that patient with repeated evaluation of the situation with change of time and clinical scenario. Dr. Matthews had firsthand information and opportunity to evaluate the patient and, having weighed the pros and cons of the risks and benefits, decided to use succinylcholine. One cannot question that judgment call. He, in fact, considered alternative approaches, including fiberoptic and blind nasal approaches to intubation. However, it is stated, “tiration of alternative drug, such as propofol, was felt to be too time consuming.”\(^2\)

Regardless of whether neuronal lesion is of several weeks’ or several months’ duration, succinylcholine-induced hyperkalemia has been observed after full recovery of motor function.\(^3,4\) In the patient described, Dr. Matthews noted that residual spasticity was still present and the patient needed the use of a cane to ambulate. This patient was initially intubated because of respiratory failure on the fifth day of admission with no adverse events. The report does not provide an account of what drugs were used to facilitate intubation the first time. Was a relaxant used at all? If not, how was the intubation achieved in this obese, hypoxemic, uncooperative patient? These data would have clarified the limitations and advantages of the technique used, and whether in fact the residual effects of spinal contusion were still present, if succinylcholine was used the first time. Unfortunately, only the intubation technique used the second time is reported.

Gronert and Theye\(^5\) wrote the first review of succinylcholine-induced hyperkalemia in Anesthesiology in 1975. Almost two decades later, based on new and relevant information, the subject was comprehensively reviewed in 1992.\(^6\) Information regarding acetylcholine receptor (AChR), its isoforms, and their responses to agonists and antagonists continues to accumulate. This was the basis for the recent review.\(^1\) During his 22 yr of clinical practice, Dr. Matthews has “personally witnessed several near airway catastrophes that followed the use of longacting nondepolarizing relaxants in similar situations.” In the case reported, the use of a depolarizing relaxant also had a catastrophic consequence. As demonstrated by the observations of Dr. Matthews, sometimes the choices deliberately made, with the best of intentions, can still result in adverse outcomes. Even 40 yr after the original reports of succinylcholine hyperkalemia, we are still uncertain, in some situations, whether it would be safe to administer or desist from succinylcholine. It is possible that persistent pancreatitis (or inflammation) by itself may up-regulate AChRs even in the absence of immobilization. Clinical observations, such as that of Matthews, and basic studies may answer these questions in the future and guide us better.

On another note, I wish to modify my thinking on a statement made on page 164 of the review. It states that 100 mg succinylcholine is capable of releasing 0.56 mM choline, a concentration outside the physiologic range and sufficient to activate α7 AChRs. We now realize that this approximate concentration of choline when redistributed would result in a much smaller concentration at the neuromuscular junction. Although this does not preclude the mechanism suggested for succinylcholine and its metabolites (succinylmonocholine and choline) to stimulate α7 AChRs, the importance of the latter in the stimulation of the α7 AChRs becomes less significant. I thank William J. Perkins, M.D. (Associate Professor, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota), for bringing this to my attention on January 24, 2006, in a personal communication via e-mail.

J. A. Jeevendra Martyn, M.D., F.R.C.A., F.C.C.M., Harvard Medical School, Massachusetts General Hospital, and Shriners Hospital for Children, Boston, Massachusetts. martyn@etherdome.mgh.harvard.edu

References


David C. Warthier, M.D., Ph.D., served as Handling Editor for this exchange.
neurologic examination revealed a tired patient with complete paralysis of the left arm, accompanied by atrophy, anesthesia (C4–C7), Horner syndrome, and tactile allodynia of the left chest. Chest x-ray and computed tomography of the chest demonstrated a left elevated diaphragm as a consequence of phrenic nerve paralysis (figs. 1 and 2). Arterial blood gas analysis revealed respiratory acidosis (in arterial blood: partial pressure of oxygen \([\text{PaO}_2]\), 47.0 mmHg; partial pressure of carbon dioxide \([\text{PaCO}_2]\), 65.1 mmHg; pH, 7.33; base excess, 5.3 mmol/L; saturation, 80%). Pain started immediately after the accident and was treated by several combinations of opioids and other analgesics, which the patient did not remember in detail. An IDDS was implanted in January 2004, with an initial daily dose of 14 mg morphine and 0.15 mg clonidine. Nearly 2 weeks later, catheter leakage and dislocation provoked a withdrawal syndrome, and after replacement of the catheter with the previous dose of morphine, cardio-pulmonary resuscitation became necessary. The patient recovered completely from this intervention. Subsequently, the morphine dosage was reduced to 2 mg/day. The exact time course of dose changes within the following months is unknown, but the dose finally increased to 4 mg morphine per day. During these last months, the patient’s psychiatric state and general condition worsened significantly.

Because of the psychological symptoms, particularly the severe tiredness and depressed mood, and the reduced pulmonary function, we suspected chronic opioid intoxication, and consequently the daily intrathecal morphine dose was reduced from 4 to 1 mg within 3 weeks and subsequently was switched to a concomitant oral medication (12 mg/day hydromorphone). In addition, 0.6 mg/day clonidine was substituted for gabapentin. Under this medication, the patient reported a considerable improvement in pain level, tiredness, and psychological state, and the dyspnea and respiratory function recovered to normal (in arterial blood: \(\text{PaO}_2\), 126.7 mmHg; \(\text{PaCO}_2\), 41.8 mmHg; pH, 7.424; base excess, 2.8 mmol/L; saturation, 98%). Obviously, the morphine effects on respiration were facilitated by (1) consequences of the accident, including phrenic nerve paralysis, elevation of the diaphragm, and atelectasis, and (2) the reduced vigilance after dose escalation. However, the key role of intrathecal morphine for the chronic deterioration of the patient’s condition was proven by complete recovery not only of the tiredness and other psychiatric symptoms but also by return to normal in all respiratory parameters and the physical capacity after morphine reduction and change to oral opioid treatment.

One reason for this case presentation was the remarkable fact that all involved physicians (neurosurgeons, neurologists, rehabilitation and pain specialists) did not recognize the correlation of increasing morphine dose without any analgesic improvements, the increasing fatigue, exercise dyspnea, and the deterioration of pulmonary function step-by-step for several months although respiratory depression with intrathecal opioids is well known. The missing anticipation of respiratory risk under long-term intrathecal morphine medication is matched by missing precautions in the cited European and German guidelines.11,12 In consequence, physician awareness is apparently limited only to acute signs of intoxication (such as bradypnea, respiratory arrest). There is an increasing number of reports such as this one revealing potentially life-threatening side effects or persistent neurologic sequelae of IDDS, and there are no controlled trials evaluating the frequency of more moderate respiratory depression or increased sleep apnea syndrome in chronic pain patients. The current patient is one of several referred to our pain clinic and treated intrathecally because of a supposed resistance to therapy. These patients were mainly diagnosed in neurosurgical or orthopedic departments with a monodisciplinary approach to pain treatment.13 Most of them—like the current patient—could be treated sufficiently without IDDS using multimodal nonmedical protocols and medical treatment, mainly including oral opioids. Therefore, treatment resistance should be diagnosed very cautiously. We recommend a reevaluation of intrathecal opioid treatment in chronic pain states considering that, in contrast to intrathecal spasmyotic treatment and oral opioid pain treatment,14–16 no randomized controlled trials are available.

**Fig. 1.** Chest x-ray. **White arrows** mark elevated left diaphragm. **C** = colon.

**Fig. 2.** Computerized, contrast-enhanced, multisliced tomography; coronary reconstruction. **White arrows** mark the right and left diaphragm; left side elevated diaphragmatic dome with compression atelectasis (*). **A** = aorta; **L** = liver; **LV** = left ventricle; **RV** = right ventricle.
The Value of Simulation Training during Anesthesia Residency

To the Editor:—It is hard to measure the intangibles of skilled anesthesia management such as leadership, planning, and dynamic problem solving, let alone to link them unequivocally to specific patient outcomes. Although simulation training has been advanced as a method to help develop crisis management and other “nontechnical” skills, proof of this link is currently incomplete. However, a recent example may highlight the value of simulation training during anesthesia residency with respect to these issues. On a recent international medical trip, the operating room’s sole oxygen supply, an H-cylinder, was accidentally knocked over, severely damaging its regulator and causing a high-pressure leak necessitating its immediate removal. Because oxygen was the only gas supplied to the anesthesia machine, all fresh gas flow to the anesthetized and paralyzed patient ceased, and the oxygen supply alarm sounded.

Options at this point included (1) hand ventilation through the circuit (taking advantage of a functional carbon dioxide-absorbing system), but diluting the alveolar anesthetic level and risking wastage of oxygen through small leaks in the circuit, or (2) apneic oxygenation from a quiescent circuit. The latter was chosen, because it would be the means most likely to maintain alveolar anesthetic and oxygen levels while freeing hands to prepare for an intravenous anesthetic. Accordingly, further ventilation was temporarily suspended, and the sidestream carbon dioxide sampling line was disconnected and capped (so as not to waste oxygen from the circuit). Fortunately, a pulse oximeter was available.

The personnel management of this situation focused on dispatching others to obtain a self-inflating ventilation bag from the recovery room (the one and only such device in the entire hospital) and making preparations for an intravenous anesthetic, while seeking a replacement for the damaged oxygen pressure regulator. In this particular event, the patient experienced 6–7 min of apnea and remained anesthetized while maintaining oxyhemoglobin saturations of 100%. When faced with an oxygen supply loss, the near explosion of an unsecured cylinder, and a loud alarm, one’s first instinct may be to vigorously ventilate the patient. However, by closing the pressure relief valve and discontinuing sidestream carbon dioxide analysis, one can ensure a 4- to 15-min oxygen supply (depending on fraction of inspired oxygen, functional residual capacity, and patient metabolism). It is not clear how long it would have taken to sort through these options from first principles under these difficult conditions without previous exposure to a similar problem during a crisis simulation course in residency (Anesthesia Crisis Resource Management, Stanford University School of Medicine, Stanford, California). In this course, trainees manage both common and novel operating room complications, allowing them to develop templates for technical and behavioral responses to such situations. The use of high-fidelity human patient simulators and recreated operating room environments in courses such as this capture both the stress and the immediacy of real patient emergencies and, ideally, provide the first exposure to plausible catastrophes in a setting where no patients’ lives are at risk. When a potentially catastrophic oxygen supply failure arose in real life, its management seemed relatively routine because, virtually speaking, I’d been there before.

Geoffrey K. Lighthall, M.D., Ph.D., Stanford University School of Medicine, Stanford, California. geoff@stanford.edu

References

5. Gaba DM, deAnda A: A comprehensive anesthesia simulation environment: Re-creating the operating room for research and training. ANESTHESIOLOGY 1998; 89:387–94

Accepted for publication April 17, 2006.

Anesthesiology 2006; 105:433 © 2006 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.
Tubing Misload Allows Free Flow Event with Smart Intravenous Infusion Pump

To the Editor—The use of “smart” intravenous infusion pumps incorporating microcomputer technology holds the promise of safer medication administration and is endorsed by ECRI (formerly the Emergency Care Research Institute).1 A sophisticated feature of smart pumps is the medication library for particular patient types or care venues. Drugs in the library are given absolute (hard) or advisory (soft) preprogrammed dosing limits. The user selects the appropriate library, drug, and concentration, thereby invoking the limits for that medication. If a limit is breached, an alarm is both seen and heard. An “anesthesia mode” within each library allows prolonged pause, alarm management, and dose limits specific for the operating room.

After an intensive multidisciplinary study that included review of safety data, a return-on-investment analysis, a failure mode and effects analysis, and a usability trial, the University of Wisconsin Hospital and Clinics selected and implemented the Alaris Medley Medication Safety System intravenous pump (ALARIS Medical Systems, Inc., San Diego, CA) in October 2003. Before use in the operating room, training to highlight pump safety features, setup, programming, and capabilities was mandated for all anesthesia providers.

The failure mode and effects analysis team was aware, via an Internet discussion group and discussions with the manufacturer, of reports describing incorrect loading of the pumping segment of the Alaris intravenous tubing. Two types of misloads involving a hard plastic upper fitment were described. The first resulted from lifting the upper fitment as the pump door was closed, thereby stretching the silicone plastic pumping segment, typically causing an underinfusion. The second type of misload was less well understood and difficult to reproduce. It was thought to involve trapping the upper fitment in a tilted position as the pump door was closed. Because of these reports, preimplementation training specifically focused on correctly loading the upper fitment.

Three weeks after pump implementation, a 58-yr-old man presented for elective coronary revascularization as the first case of the day. Preoperative anesthesia equipment setup included Alaris intravenous pumps mounted at eye level to facilitate reading the programming screen. One tubing set was primed with nitroglycerin and loaded, and the pump module door was closed and latched. The pump was turned on, the infusion was programmed and placed into prolonged pause as indicated by a yellow light at the top of the pumping module. The tubing was connected to a primed carrier fluid system that included a stopcock manifold (Merit Medical Systems, Inc. South Jordan, UT) and narrow bore extension tubing (Arrow International Inc., Reading, PA). Roller clamps and manifold stopcocks were opened to allow immediate initiation of therapy as necessary; however, the extension tubing that would eventually connect the manifold to the patient's central venous line remained clamped. The patient was brought to the operating room. After induction of anesthesia and preparation for surgery, the extension tubing from the manifold was connected to the infusion port of the central venous catheter (MAC; Arrow International, Inc.). Later, the clamp on the extension tubing was opened to allow the slow infusion of carrier fluid via the manifold.

Almost immediately, and for no readily apparent reason, the patient's arterial pressure decreased and required repeated treatment with bolus administration of vasopressors by syringe. Transesophageal echocardiography revealed a marked decrease in left ventricular end-diastolic volume and function. The blood pressure recovered within minutes. Only then was the nitroglycerin bottle supplying the infusion pump found to be completely empty. A free-flow malfunction of the pump was suspected.

Close examination of the nitroglycerin pump module revealed a gap at the top of the door (fig. 1). The pump in question was removed and sequestered. Surgery proceeded without incident. Postoperatively, the patient was found to be neurologically at baseline and without untoward sequelae.

The sequestered pump was photographed, and the databases within the control and pump module were downloaded. Visual examination revealed that part of the intravenous tubing, the upper fitment, a molded hard plastic flange designed to be loaded from above into a recess, had been “front loaded” and held in place by the flange as the door was closed. The pump door was open sufficently to latch and to open the flow-stop slide clamp below the pumping mechanism. The tubing flange held the door away from the reticulating finger pumping mechanism that normally sequentially occludes the tubing and controls flow. When the tubing is designed as designed and the pump is off or paused, the fingers press the tubing against the door and completely prevent flow. In this event, the reticulating fingers could not reach the door, the tubing was not occluded, and free flow occurred.

Review of the downloaded pump databases revealed that during the setup, the pump alarmed twice before the audio and visual alarm indicators were cancelled when the pump was placed in prolonged pause. The alarm message displayed was “Fluid side occlusion.”

Three issues are particularly concerning. First, the failure mode and effects analysis conducted before the implementation of the pumps was lengthy and thorough but did not predict the failure mode causing

---

Supported by grant No. 1 UC1 HS014253-01 from the Agency for Healthcare Research and Quality, Rockville, Maryland (Principal Investigator: Dr. Carayon), and the University of Wisconsin Department of Anesthesiology, Madison, Wisconsin. Dr. Schroeder visited ALARIS Medical Systems, Incorporated, as a member of a team representing the University of Wisconsin Hospital in May 2003 at the expense of Alaris. In August 2005, Dr. Schroeder became a consultant to Cardinal Health, Incorporated. The opinions expressed are those of the authors and not do not necessarily reflect those of Cardinal Health, Incorporated, or its affiliates.

Anesthesiology. V 105, No 2, Aug 2006

© 2006 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

---

Fig. 1. The Alaris Medley Medication Safety System intravenous pump viewed from above. The black arrow indicates the door gap caused by “front loading” the hard plastic upper fitment. The white arrow indicates a normal door gap on another pumping module.
the frank free flow we report. Second, the alarm message displayed during setup indicated an occlusion as opposed to a potential free flow, a message that did not alert the user to the fault. Finally, this event occurred despite intensive user training before implementation that emphasized correct upper fitment loading.

We believe other factors also contributed to this event. Because the pump was mounted at eye level, the door gap at the top was not visible. It is likely that time pressure, distraction from other setup activity in the operating room, and the practitioner’s inexperience clinically with the new pump increased the likelihood of this event.

Clinical introduction of new products may result in unanticipated consequences despite preintroduction evaluation, institution-specific usability testing, and carefully planned user training. Such training cannot be relied on to overcome design flaws in equipment.

This incident was reported through the US Food and Drug Administration reporting system. The manufacturer has since modified the pump module and error messages to reduce the risk of free flow from this cause.

Mark E. Schroeder, M.D.,* Richard L. Wolman, M.D., Tosha B. Wetterneck, M.D., Pascale Carayon, Ph.D. *University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. meschro2@wisc.edu

The authors thank Paul R. Malischke, B.S.E.E. (Anesthesia Equipment Manager, University of Wisconsin Hospital and Clinics, Madison, Wisconsin).

References

3. Hazard report: Alaris Medley medication safety system LVP module can permit gravity flow if sets are misloaded. Health Devices 2004; 33:443–5

(Accepted for publication April 17, 2006.)